Ipsen : to present new data at 13th Annual Conference of the International Liver Cancer Association (ILCA 2019) -Today at 10:24 am
Results from a matching-adjusted indirect comparison suggest that cabozantinib provides two additional months of progression-free survival versus regorafenib in the second-line treatment...